It is unclear whether this failure to achieve therapeutic benefit is related to the reduced affinity of crizotinib for the ATP-binding pocket of oncogenically activated ALK mutants, the overexpression of MYCN often observed in neuroblastoma, or a combination of these and other factors. This evidence concerns the gene ALK and neuroblastoma.